Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, 136 patients had received post-HSCT i.t. treatment (i.t. group) and 261 had not (non-i.t. group). The two groups were, apart from the i.t. therapy given or not given, at equal risk of post-HSCT central nervous system (CNS) relapse, which was the primary endpoint studied. Isolated CNS relapses were observed in 2 (1.5%) patients from the i.t. group and 2 (1%) from the non-i.t. group. Combined relapses, including CNS, involved 4 (3%) patients from the i.t. group and 6 (2%) from the non-i.t. group. Overall survival and the occurrence of neurological side effects did not differ significantly between the groups. There was no statistically significant difference in the incidence of isolated or mixed CNS relapses between the two groups, suggesting little or no benefit from i.t. therapy post-HSCT in children.
Introduction
A relapse of leukemia disease is the most common cause of failure of treatment after hematopoietic SCT (HSCT), and the majority of patients develop systemic relapse. The incidence of central nervous system (CNS) relapses of leukemia after HSCT range from 2-5.5% among patients without previous CNS disease to 11-27% among patients with CNS involvement of malignant disease pre-HSCT. [1] [2] [3] Although modern conventional therapy with intensive intrathecal (i.t.) therapy pre-HSCT has reduced the rate of CNS relapse to 2-10%, the evidence for the usefulness of prophylactic i.t. therapy post-HSCT is limited. 4 A recent study involving 1226 adult patients with ALL, AML and CML found a slightly higher rate of CNS relapse after HSCT in the group receiving i.t. therapy. However, the data analysis was complicated by the fact that i.t. therapy was administered to a larger extent in patients with CNS disease before transplant, resulting in a difference in disease severity between the two groups. 5 A survey conducted by the European Group for Blood and Marrow Transplantation (EBMT) in 2005 was carried out to describe the current practice concerning i.t. prophylaxis in HSCT. Ninety centers participated, of which 42 (47%) had never used pre-nor post transplant i.t. prophylaxis, Pre-transplant, i.t. therapy (i.t. therapy close to HSCT) was given at 48 centers (53%) to selected groups, whereas only 29 centers (32%) were found to use post transplant i.t. therapy. The EBMT study group concluded that routine i.t. prophylaxis should not be given to patients without prior CNS involvement, but the study did not evaluate the efficacy of i.t. therapy. 6 In our previous study we involved 120 patients from transplantation centers at Karolinska University Hospital in Huddinge, Stockholm and Uppsala University Children's Hospital, comparing the outcome of regimens with and without i.t. therapy after HSCT. There was no statistically significant difference in the incidence of CNS relapse between the groups with only one patient in each group with a CNS relapse. 7 In this study, we have expanded our previous study of 120 patients, adding four transplantation centers to include retrospective data from six European pediatric HSCT centers, resulting in a total of 397 patients. Of the original 120 patients, 115 were included in the expanded study. The overall similar treatment and conditioning regimens at the participating centers created the opportunity to evaluate the need for, and the potential risks of, i.t. therapy to children post-HSCT, through the comparison of the treatment outcomes of the two differing i.t. therapy regimens used.
Patients and methods

Patient characteristics
The study population consisted of 397 patients who underwent allogeneic HSCT for ALL or AML between 1 January 1992 and 31 December 2006. All children were between 0 and 18 years old at the time of HSCT. Transplanted patients who had additional serious metabolic or neurological diseases were not included in the study (three patients). Six patients, whose post-HSCT data were unavailable, were omitted from the study. The i.t. treatment was started at median day 32 (range 0-127) post-HSCT and patients who died or relapsed within 90 days post-HSCT were excluded as we considered that the effect of the i.t. therapy on relapse or survival could not be evaluated earlier than 3 months after HSCT.
Participating centers from Sweden included the Karolinska University Hospital, Stockholm (98 patients), Sahlgrenska University Hospital, Gothenburg (43 patients), Lund University Hospital, Lund (22 patients) and Uppsala University Hospital Sweden (52 patients). These centers followed the Nordic Organization for Hematology and Oncology (NOPHO) treatment protocols.
The study also included the Helsinki University Central Hospital, Finland (131 patients) and Utrecht University Hospital in the Netherlands (51 patients). The Finnish center followed the NOPHO treatment protocols and the Utrecht center followed the Dutch Childhood Oncology group (DCOG) protocol. Two centers did not administer i.t. prophylaxis to patients. At the centers administering i.t. prophylaxis post-HSCT, the indications differed slightly between the centers. One center gave i.t. prophylaxis only to selected cases with prior CNS involvement and one center gave i.t. therapy to all ALL patients with previous CNS disease or pre-HSCT relapse. The third center administered post-HSCT i.t. therapy to all ALL patients and to high-risk AML patients where the AML patients generally considered to be high risk were AML FAB M4-M7 and AML FAB M0-M3 patients with a high presenting leukocyte count (WBC) (420 Â 10 9 /L) or another high-risk factor such as extramedullary involvement or slow response to primary treatment [8] [9] [10] (Table 1 ). The fourth center gave i.t. therapy post-HSCT to all ALL and AML patients.
Of the 397 patients, 273 patients were diagnosed with ALL and 118 children were diagnosed with AML. Six patients were diagnosed as acute undifferentiated leukemia (Table 1) .
In all, 136 children received i.t. therapy and 261 children did not receive i.t. therapy.
Transplantation procedure
In the 397 patients, the sources of stem cells were BM in 81% of the patients, PBSC and cord blood in 19% of the patients.
Matched unrelated donors were used for the transplantation in 52% of the patients, with 43% of the patients receiving stem cells from a sibling donor and the remaining 5% of patients underwent transplantation from a haploidentical donor.
Additional Etoposide was given at some of the participating centers if morphological CR was not received before HSCT. Etoposide, as part of conditioning therapy regardless of CR, was given for 12/136 (9%) of patients in the i.t. group and 28/261 (11%) of patients in the non-i.t. group. When comparing the number of patients receiving Etoposide (regardless of the reason for giving Etoposide), the administration was evenly distributed between the groups (Table 1) . Two major chemotherapeutic regimens were used for conditioning: TBI, 3 Gy for 4 days (total dose 12 Gy) and CY 60 mg/kg/daily i.v once daily on days 1 and 2 (total dose 120 mg/kg) or BU 4 mg/kg p.o in divided doses for 4 days (total dose 16 mg/kg) and CY 60 mg/kg/daily i.v once daily on days 1 and 2 (total dose 120 mg/kg). In all, 316 patients (80%) received TBI as part of conditioning therapy (Table 1) .
I.t. therapy was administered six times, with 2 week intervals at centers administrating post-HSCT, starting 1 month after HSCT. Patients with previous CNS leukemia had a prolonged treatment regimen with i.t. injections every 8 weeks for 18 months post-HSCT. The prolonged treatment schedules did vary in time depending on side effects and other diseases/complications. I.t. injections were generally not given if total plt counts o50 ( Â 10 9 /L) or WBC o1.0 ( Â 10 9 /L). Low plt count, infections or other complications often delay the start of i.t. therapy until the second or third month after HSCT. The usual practice was for patients to receive cytarabine (six injections) or Mtx (six injections) as an alternative. The dose is age dependent: 16 mg cytarabine or 6 mg Mtx at o1 year of age; 20 mg cytarabine or 8 mg Mtx at 1-2 years of age; 26 mg cytarabine or 10 mg Mtx at 2-3 years of age; and finally 30 mg cytarabine or 12 mg Mtx over 3 years of age.
Methods
The study retrospectively compared the outcome of HSCT between patients receiving post-HSCT i.t. therapy and patients who did not receive post-HSCT i.t. therapy. Diagnoses, treatment, relapses, types of relapses, complications and other patient data were retrieved from patient charts. The study period was 192 months (1 January 1992-31 August 2008).
The primary endpoint investigated was the incidence of CNS relapse. Secondary endpoints considered were other types of relapse, time to relapse, GVHD, neurological complications and death. Three parameters were registered retrospectively to reveal possible neurological affliction: all incidents with severe neurological symptoms after HSCT, the activities of daily living score and school performance as a determinant of cognitive function. A neurological side effect was defined as one of the following: seizures, cerebrovascular disease, peripheral neuropathy, altered consciousness, visual disturbances, serious/repeated headaches or cognitive difficulties. The activities of daily living score was estimated retrospectively and was based on clinical observations of motor/development skills and overall well-being and physical health as noted in the chart. The Lansky score was used for children under 16 years of age and the Karnofsky score was used for adolescents 16-18-years old. 11, 12 Activities of daily living score and school performance were registered for each child 1 year after HSCT and at the end of follow-up.
The number and type of neurological complications were registered so the potential beneficial effects of i.t.therapy (that is, reduction in the incidence of CNS relapse) could be evaluated against any negative neurological side effects of the i.t. therapy. The level of statistical significance was set at Po0.05. The study would require 1500 subjects per group to detect a difference of 1% in CNS relapse post-HSCT between the groups, as the outcome is very rare (estimated to be 2-5.5% without previous CNS involvement and 11-27% with prior CNS involvement). However, the study size was determined by the number of patients available for inclusion. With 397 patients included, the power of the results to detect an absolute difference in outcome of 5% between the groups studied is 80%.
The study was approved by the Regional Ethics Committee at the Karolinska Institutet, Stockholm.
Results
The i.t. group consisted of 136 patients: 107 ALL patients and 29 AML patients, with a mean age of 9.2 years at transplantation. Thirty-one of the i.t. patients (23%) had previous CNS involvement at diagnosis or pre-HSCT CNS relapse of their leukemia. The non-i.t. group comprised 261 children, 166 with ALL, 89 children with AML and 6 children with acute undifferentiated leukemia, with a mean age of 8.7 years. Thirty-five (13%) of these patients had previous CNS leukemia ( Table 1) . The difference in pre-HSCT CNS involvement was not statistically significant. The median follow-up time was 4.2 years (range 3 months to 15 years). In patients with BM morphological CR, with o5% blasts, pre-HSCT was found equally distributed between the groups. The i.t. group had a statistically significantly higher proportion of cases given pre-HSCT CNS irradiation ( Table 2 ).
The first dose of i.t. therapy post-HSCT was given at median day þ 32 (range day þ 1 to þ 127 post-HSCT) and the patients were given 6 (median) doses (range 1-15 doses). Cytarabine and Mtx were used equally with 40% given a full course of cytarabine and 38% Mtx. Twenty-two percent received both cytarabine and Mtx injections during their i.t. therapy course. In these cases the drug was changed from the original cytarabine or Mtx. during the course of i.t. therapy because of adverse reaction to either drug or presence of GVHD (Mtx preferred at some centers).
Isolated CNS relapses were observed in two (1.5%) patients from the i.t. group and two (1%) from the non-i.t. group. None of the patients had a history of earlier CNS disease. In one patient in the non-i.t. group, the isolated CNS relapse was the third relapse post-HSCT (Table 3) . Combined relapses including CNS were observed in four (3%) patients from the i.t. group and six (2%) from the non-i.t. group (Table 4) . There was no statistically significant difference in the total number of relapses or death because of relapse between the groups; in the i.t. group 48 patients (35.5%) had relapse of malignant disease and 29 (58%) died, whereas in the non-i.t. group there were 68 patients with relapse (26%) and 56 patients (58%) died. There was no statistically significant difference in the incidence of CNS relapse, with two cases reported in both the i.t. group and the non-i.t. group (Table 4) . The cumulative proportion of surviving patients was equal between the groups (Figure 1 ). Overall survival did not differ significantly between the groups. In all, 50/136 patients in the i.t. group (39%) died and 96/261 (37%) in the non-i.t. group died (Table 4) .
In a sub-analysis of the patients with pre-HSCT CNS involvement of leukemia; 31 patients from the i.t. group and 35 patients from the non-i.t. group were observed. There was no difference in the incidence of relapse or death (Table 5 ). There was no post-HSCT CNS relapses among these patients. Among the patients with pre-HSCT CNS involvement, there were 29 'CNS-untreated' patients given either pre-HSCT CNS irradiation or i.t. therapy after HSCT. There were no differences in outcome between these 'CNS-untreated' patients and the 15 patients given both pre-HSCT CNS irradiation and i.t. post-HSCT. Sixteen patients with pre-HSCT CNS involvement were given i.t. therapy post-HSCT but no pre-HSCT CNS irradiation, and six patients received pre-HSCT CNS irradiation and no post-HSCT i.t. therapy. When compared to the 29 'CNS-untreated' patients, there were no differences in outcome between the CNS-treated group and the 'CNSuntreated' group. During follow-up, 11% developed neurological complications in the i.t. group as opposed to 10% in the non-i.t. group. With regard to the type of complication, seven patients in the i.t. group had cognitive difficulties compared to eight from the non-i.t. group. The difference between the groups in the number of cognitive-and other-neurological complications was not statistically significant.
The majority of the children attended a school class that corresponded to their age both at 1 year post-HSCT and at the end of follow-up and there was no difference in school performance between the two groups. The Lansky/Karnofsky scores for the surviving children were reassuringly high in both groups: 91% (mean) at 1 year after HSCT and 97% at the end of follow-up in the i.t. group (range 40-100%) and for the non-i.t. group 94 and 95%, respectively (range 50-100% at 1 year after HSCT and 60-100% at last follow-up).
Discussion
In this retrospective study, we have compared data from six pediatric centers where two different regimens of i.t. therapy post-HSCT are used. We could not show a beneficial effect of prophylactic i.t. chemotherapy on the incidence of CNS relapse, BM relapse, other relapses or death after HSCT. The low incidence of CNS relapse of 1-2% after HSCT is similar to the rate presented in our earlier study, as well as in a recent study, involving adult patients. 5, 7 None of the four patients with isolated CNS relapses had a previous CNS disease. Two of them received i.t. treatment and two of them pre-HSCT CNS irradiation. In one of the patients the isolated CNS relapse was the third relapse post-HSCT (Table 3) .
The only study showing beneficial effects of i.t. therapy post-HSCT reported a rate of CNS relapse significantly higher than ours (13% opposed to 1-3%). However, this study was conducted more than 20 years ago. 1 With the advent of new drugs, treatment schedules and more efficient CNS prophylaxis, this has gradually changed over time. This could render the evidence supporting the use of post-HSCT i.t. therapy for leukemia out dated.
The advantages of not giving i.t. therapy after HSCT are many, in both practical and psychological terms. When given, the i.t. injection carries a risk of bleeding into the CSF and a risk for CNS infection. Spinal subdural hematoma is another severe and rare complication of lumbar puncture, which can lead to paraparesis. [13] [14] [15] Apart from the acute complications of injection, the long-term sequeale of i.t. Mtx are well documented. A higher risk for leukoencephalopathy has also been documented after post-HSCT i.t. Mtx. 1 Cytarabine, currently the most common drug used, is not considered to be associated with as many complications as Mtx. However, all the injection-related risks still apply.
New studies need to be performed to recommend a more restrictive policy in using post-HSCT i.t. prophylaxis and large study groups are needed as the outcome is rare. To detect a difference in CNS relapse post-HSCT of 1% we estimated that 1500 subjects per group would be needed. With our current sample size of 397 patients, the power of the results is 80% to detect an absolute difference in outcome of 5% between the groups studied.
Our material of 397 patients originates from six different centers but the groups are comparable despite slightly differing treatment schedules, and the disease burden is equal between the groups. BM morphological CR, the incidence of CNS disease before HSCT and cytogenetic factors predisposing for poor prognosis (including t (4; 11), t (9; 22)) are equally distributed between the groups. The percentage of ALL was higher in the i.t. group but showed a P-value of 0.05 of 'borderline' significance.
In an attempt to further analyze this parameter a regression analysis was performed. Owing to small numbers and the rarity of the outcome we could not show that ALL was a determining factor for CNS relapse. The data show higher WBC counts at diagnosis in the i.t. group, but unfortunately there are a considerable number of missing data on WBC at diagnosis which is why we believe that the difference between the groups is very uncertain. Despite the missing data, the difference in WBC at diagnosis between the groups is not a strong enough factor to render the groups incomparable when weighed against the other parameters.
There were a higher proportion of patients with CNS irradiation in the i.t. group when compared to the non-i.t. group. This could contribute to a lower than expected relapse rate in the i.t. group if there was a significant isolated effect (or additive to i.t. therapy) of pre-HSCT CNS irradiation, which reduced CNS relapses post-HSCT. This would make the results of the treatment effect of i.t. therapy difficult to interpret. This was not evident as all other relevant parameters were comparable in the groups where the CNS-relapse rate was equal. We concluded that the higher proportion of CNS irradiation in the i.t. group did not interfere with the endpoints studied nor with the possibility to draw conclusions from the results of the study. We cannot however draw any conclusions on the specific efficacy of pre-HSCT irradiation on post-HSCT relapses or survival as the study was not designed to answer this question.
The tools at hand for detecting neurological complications or cognitive sequelae in this retrospective study were level of schooling (described in the Methods section) and the Lansky/Karnofsky score. These are not specific parameters to detect neurological or cognitive sequelae but they do provide valuable and comparable information on the level of neurological function of the patient. 16, 17 The observation period extends to only 192 months, and these complications and sequelae can occur and/or develop later post-HSCT. With the tools available, we could not identify any difference in the cognitive outcome between the patients with and without i.t. therapy post-HSCT.
Owing to the study size we could not investigate possible determinant factors for post-CNS relapse, but our results strengthen the idea that i.t. post-HSCT does not have an additive protective effect against CNS relapse post-HSCT. This is also supported by the analyses of the subgroup of the 66 patients with pre-HSCT CNS involvement. In this group no protective effect on post-HSCT relapse or death was seen with either pre-HSCT CNS irradiation or post-HSCT i.t. therapy or the combination of both.
In summary, retrospective analysis of the outcome of 397 pediatric patients showed no difference in the rate of CNS leukemia relapse, nor any difference in the overall relapse frequency and mortality between the groups with different treatment regimens of i.t. therapy post-HSCT. Although our cohort is only powered to detect a 5% increase in relapse, and small differences in relapse could be seen with a larger cohort, we do not see evidence in this mixed cohort that supports the use of post-HSCT IT therapy. It is possible that high-risk populations could be defined, which may benefit from this therapy. Until such a cohort is defined, patients should be assessed individually for risk of CNS relapse and the suitability of post-HSCT IT therapy.
